산처리(酸處理)에 따른 상아질(象牙質)에 대한 Glassionomer Cement의 접착강도(接着强度)에 관(關)한 실험적(實驗的) 연구(硏究)

이원섭,민병순,최호영,박상진,Lee, Won-Seob,Min, Byung-Soon,Choi, Ho-Young,Park, Sang-Jin 대한치과보존학회 1988 Restorative Dentistry & Endodontics Vol.13 No.1

The purpose of this study was to evaluate the bond strength of glassionomer cement against cut dentin surface which was treated with various surface cleaning agents. 48 freshly extracted human 3rd molars were ground flat through the enamel into the dentin using 600 grit silicone carbide paper under a flow of water. The were divided into four groups by the following cleaning procedure on cut dentin surface; Group I : No surface treatment after grinding with 600 grit silicone carbide paper as control group Group II : Surface treatment with 50% citric acid for 30 seconds. Group III : Surface treatment with 37% phosphoric acid for 30 seconds. Group IV : Surface treatment with 10% poly acrylic acid for 30 seconds. The specimens in 4 groups were immersed in distilled water at $37^{\circ}C$ for 24 hours before testing after cleanising with water-spray and drying with air. Bond strength was measured with Instron Universal Testing Machine (Autograph S-100, Shimadzu, Kyoto, JAPAN). The results were as follows: 1. The bond strengths of group II, III & IV were not seemed to be shown more significant improvement than a group I. 2. The bond strengths in groups which were treated with 50% citric acid, 37% phosphoric acid and 10% polycrylic acid, were ranked 24.70kg/$cm^2$, 22.02kg/$cm^2$ and 31.13kg/$cm^2$, but its difference was not significant, statistically.

주제 중심의 크롤링 방법

이원섭 ( Won-seob Lee ),신재문 ( Jea-moon Shin ),임지호 ( Ji-ho Lim ),김단이 ( Dan-i Kim ),조경일 ( Kyung-ill Cho ) 한국정보처리학회 2017 한국정보처리학회 학술대회논문집 Vol.24 No.2

크롤링을 통해서 주제와 관련된 데이터를 판단한다. 주제와 관련성을 위해서 가중치를 사용하고 정확도와 크롤링 속도를 위해 응집력과 중복성 검사 등을 사용한다.

이득 보상을 고려한 정확한 주파수 추정

박철원(Chul-Won Park),이종수(Jong-Su Lee),이원섭(Won-Seob Lee) 대한전기학회 2010 대한전기학회 학술대회 논문집 Vol.2010 No.7

The frequency as a key index of power quality can be indicative of system abnormal conditions and disturbances. As most conventional frequency estimation schemes are based on DFT filter, it has been pointed out that the gain error by changes in magnitude could cause the defects when the frequency is deviated from nominal value. This paper presents an advanced frequency estimation technique using gain compensation. To evaluate the performance of the proposed technique, the 765㎸ T/L system in Korea is simulated by EMTP-RV s/w. The proposed technique can reduce the gain error caused when the power system frequency deviates from nominal value.

CFD 해석방법을 이용한 PFA 라이닝 볼밸브의 유량계수 예측

전홍필(Hong-Pil Jeon),이원섭(Won-Seob Lee),김철수(Chul-Soo Kim),이종철(Jong-Chul Lee) 한국유체기계학회 2016 한국유체기계학회 논문집 Vol.19 No.4

IIIB 병기 비소세포폐암에서 Paclitaxel과 Cisplatin을 이용한 선행항암화학요법과 동시 항암화학방사선치료

강기문(Ki Mun Kang),이경원(Gyeong Won Lee),강정훈(Jung Hoon Kang),김훈구(Hoon Gu Kim),이원섭(Won Seob Lee),채규영(Gyu Young Chai) 대한방사선종양학회 2006 Radiation Oncology Journal Vol.24 No.4

목 적: III 병기 비소세포폐암의 치료는 항암화학요법, 수술, 방사선치료가 포함된 병용치료가 표준방법으로 알려져 있다. 본 연구에서는 IIIB 병기 비소세포폐암에서 paclitaxel과 cisplatin을 이용한 선행항암화학요법과 동시 항암화학 방사선치료를 시행하여 그 효과에 대하여 알아보고자 하였다. 대상 및 방법: 2000년 7월부터 2005년 10월까지 IIIB 병기 비소세포폐암으로 선행항암화학요법과 동시 항암화학방사선치료를 받았던 39명을 대상으로 하였다. 선행항암화학요법은 3주 간격으로 paclitaxel (175 mg/m2)과 cisplatin (75 mg/m2)을 1일째와 21일째 정맥투여하였다. 동시 항암화학요법은 43일째, 50일째, 57일째, 71일째, 78일째, 85일째 paclitaxel (60 mg/m2)과 cisplatin (25 mg/m2)을 정맥투여하였다. 흉부방사선치료는 1회 1.8 Gy씩, 주 5회 분할조사하였으며 총방사선량은 54∼59.4 Gy이었다(중앙값: 59.4 Gy). 결 과: 추적관찰기간은 6∼63개월이었으며 중앙추적관찰기간은 21개월이었다. 선행항암화학요법 후 치료반응은 부분반응 41.0% (16명), 무반응 59.0% (23명)였다. 동시 항암화학방사선치료 후 치료반응은 완전관해가 10.3% (4명),부분반응 41.0% (16명), 무반응 49.7% (19명)로 치료 반응률은 51.3%였다. 1년, 2년, 3년 생존율은 각각 66.7%,40.6%, 27.4%였으며 중앙 생존기간은 20개월이었다. 1년, 2년, 3년 무진행 생존율은 각각 43.6%, 24.6%, 24.6%였으며 중앙 무진행 생존기간은 10.7개월이었다. 동시 항암화학방사선치료 후 부작용으로 3도 이상의 식도염은 46.3%(18명), 폐렴은 28.2% (11명)에서 발생하였다. 결 론: IIIB 병기 비소세포폐암에서 paclitaxel과 cisplatin을 이용한 선행항암화학요법과 동시 항암화학방사선치료를 시행한 결과 비교적 효과적이었다. 그러나 식도염과 폐렴이 많아 부작용을 줄이기 위해 적절한 항암제의 선택 또는 방사선치료와의 병용치료의 변화가 필요할 것으로 판단되었다. Purpose: Combined modality therapy including chemotherapy, surgery and radiotherapy is considered the standard of care for the treatment of stage III non-small cell lung cancer (NSCLC). This study was conducted to evaluate the efficacy of paclitaxel and cisplatin with induction chemotherapy followed by concurrent chemoradiotherapy for stage IIIB NSCLC. Materials and Methods: Between July 2000 and October 2005, thirty-nine patients with stage IIIB NSCLC were treated with two cycles of induction chemotherapy followed by concurrent chemoradiotherapy. The induction chemotherapy included the administration of paclitaxel (175 mg/m2) by intravenous infusion on day 1 and treatment with cisplatin (75 mg/m2) by intravenous infusion on day 1 every 3 weeks. Concurrent chemoradiotherapy included the use of paclitaxel (60 mg/m2) plus cisplatin (25 mg/m2) given intravenously for 6 weeks on day 43, 50, 57, 71, 78 and 85. Thoracic radiotherapy was delivered with 1.8 Gy daily fractions to a total dose of 54∼59.4 Gy in 6∼7 weeks (median: 59.4 Gy). Results: The follow up period was 6∼63 months (median: 21 months). After the induction of chemotherapy, 41.0% (16 patients) showed a partial response and 59.0% (23 patients) had stable disease. After concurrent chemoradiotherapy, 10.3% (4 patients) had a complete response, 41.0% (16 patients) had a partial response, and the overall response rate was 51.3% (20 patients). The 1-, 2-, 3-year overall survival rates were 66.7%, 40.6%, and 27.4% respectively, with a median survival time of 20 months. The 1-, 2-, 3-year progression free survival rates were 43.6%, 24.6%, and 24.6%, respectively, with median progression free survival time of 10.7 months. Induction chemotherapy was well tolerated. Among 39 patients who completed the entire treatment including chemoradiotherapy, 46.3% (18 patients) had esophagitis greater than grade 3 and 28.2% (11 patients) had radiation pneumonitis greater than grade 3. Conclusion: Paclitaxel and cisplatin with induction chemotherapy followed by concurrent chemoradiotherapy for stage IIIB NSCLC seems to be an effective treatment. Occurrence of esophagitis and pneumonitis represents a significant morbidity and suggests a modification of the treatment regimen, either with the chemotherapy schedule or with radiotherapy treatment planning.

고령의 국소 진행된 식도암환자에서 동시 항암화학방사선치료

정배권(Bae Kwon Jung),강기문(Ki Mun Kang),이경원(Gyeong Won Lee),강정훈(Jung Hoon Kang),김훈구(Hoon Gu Kim),이원섭(Won Seob Lee),채규영(Gyu Young Chai) 대한방사선종양학회 2009 Radiation Oncology Journal Vol.27 No.2

목 적: 국소 진행된 식도암으로 동시 항암화학방사선치료를 시행한 고령의 환자들을 대상으로 동시 항암화학방사 선치료에 대한 효과를 알아보고자 하였다. 대상 및 방법: 2001년 1월부터 2007년 7월까지 병리학적 편평상피세포암으로 확인 된 65세 이상의 식도암 환자 중 동시 항암화학방사선치료를 받은 28명을 대상으로 후향적 분석을 하였다. 환자의 병기는 IIa 8명(28.8%), IIb 10명(35.7%), III 10명(35.7%)이었다. 방사선치료는 6 MV 또는 10 MV X-선으로 45∼63 Gy (중앙값: 59.4 Gy)를 분할 조사하였다. 항암화학요법은 방사선치료 시작과 동시에 Cisplatin 75 mg/m2을 제1일에 정주하였고, 5-FU는 1,000mg/m2을 제1일에서 제4일까지 4일간 지속적 정주하여 방사선치료 동안은 3주 간격으로 2회 시행하였고, 방사선치료 후 2회의 항암화학요법을 추가 시행하였다.결 과: 추적관찰기간은 3∼72개월(중앙값: 19개월)이었다. 동시 항암화학방사선치료 후 치료 반응은 완전관해가39.3% (11명), 부분반응은 50.0% (14명), 무반응이 10.7% (3명)로 치료 반응률은 89.3% (25명)이었다. 전체 환자의 1, 2, 3년 생존율은 각각 55.9%, 34.6%, 24.2%이었고 중앙 생존기간은 15개월이었다. 완전관해, 부분반응, 무반응의 종양 반응을 보인 환자들의 2년 생존율은 각각 46.2%, 33.%, 0%이었다. 생존율과 관련된 예후인자로서 병기와 방사선치료 후 종양 반응이 유의하였다. 치료에 의한 합병증으로 사망한 환자는 없었다. 결 론: 고령의 국소 진행된 식도암환자에 대한 동시 항암화학방사선치료는 심각한 부작용 없이 비교적 효과적이었다. Purpose: The effect of concurrent chemoradiotherapy was analyzed in elderly patients when used in the treatment of locally advanced esophageal cancer. Materials and Methods: The retrospective analysis included 28 elderly patients aged 65 or older, with histopathologically confirmed squamous cell carcinoma of the esophagus, underwent concurrent chemoradiotherapy from January 2001 to July 2007. The squamous cell carcinoma disease stages included 8 patients (28.8%) in stage IIa, 10 patients (35.7%) in stage IIb, and 10 patients (35.7%) in stage III. Fractionated radiotherapy was performed with a 6 MV or 10 MV X-ray for 45∼63 Gy (median: 59.4 Gy). Chemotherapy was applied concurrently with the initiation of radiotherapy. A 75 mg/m2 dose of Cisplatin was intravenously administered on day 1. Further, 5-FU 1,000 mg/m2 was continuously administered intravenously from days 1 to 4. This regimen was performed twice at 3-week intervals during radiotherapy. Two cycles of consolidation chemotherapy was performed after radiotherapy. Results: The follow-up period was 3∼72 months (median: 19 months). The treatment responses after concurrent chemoradiotherapy included a complete response in 11 patients (39.3%), a partial response in 14 patients (50.0%), and no response in 3 patients (10.7%). The overall response rate was 89.3% (25 patients). The overall 1-, 2- and 3-year survival rates were 55.9%, 34.6% and 24.2%, respectively. The median survival time was 15 months. Two-year survival rates of patients with a complete response, partial response, and no response were 46.2%, 33.0%, and 0%, respectively. The stage and tumor response after concurrent chemoradiotherapy were statistically significant prognostic factors related with survival. No treatment-related deaths occurred in this study. Conclusion: Concurrent chemoradiotherapy is a relatively effective treatment without serious complications in elderly patients with locally-advanced esophageal cancer.

파워포인트(MS-PowerPoint) 인쇄UI의 개선안 제안

허병일(Byeong Il Huh),임재성(Jae Sung Rim),이원섭(Won Seob Lee),김신우(ShinWoo Kim) 한국HCI학회 2016 한국HCI학회 학술대회 Vol.2016 No.1